Document is current

Any future updates will be listed below

CDK4/6 inhibition provides additional efficacy in HER2+, HR+ breast cancer

Crossref DOI link: https://doi.org/10.1038/s41571-026-01133-2

Published Online: 2026-02-17

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark